{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:53:05Z","timestamp":1775515985653,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013302","name":"King Abdullah International Medical Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Vancomycin remains a key medication in treating infections in pediatric patients, particularly those caused by methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA). Conventional trough-based monitoring has shown limited accuracy in predicting therapeutic exposure and nephrotoxicity. Recent guidelines recommend area under the concentration\u2013time curve (AUC)-based monitoring, but pediatric evidence remains scarce. Our objective is to assess the feasibility of vancomycin AUC\n                      <jats:sub>24<\/jats:sub>\n                      monitoring using peak\u2013trough concentrations in routine pediatric clinical practice and examine its correlation with the trough levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective, multicenter study in 70 pediatric inpatients receiving vancomycin at two tertiary hospitals in Riyadh, Saudi Arabia. Vancomycin AUC\n                      <jats:sub>24<\/jats:sub>\n                      was calculated using first-order pharmacokinetics from peak and trough levels. AUC\n                      <jats:sub>24<\/jats:sub>\n                      was compared with the trough concentrations and dosing regimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Implementation of AUC\n                      <jats:sub>24<\/jats:sub>\n                      -based monitoring was feasible in routine pediatric workflow. Pharmacists successfully calculated AUC\n                      <jats:sub>24<\/jats:sub>\n                      using the Sanford Guide mobile app, with minimal training required for nurses on sampling. The correlation between the trough levels and AUC\n                      <jats:sub>24<\/jats:sub>\n                      was strong (\u03c1 = 0.789, p &amp;lt; 0.001), but the trough values did not consistently predict target attainment (AUC\n                      <jats:sub>24<\/jats:sub>\n                      400 \u03bcg h\/mL\u2013600\u00a0\u03bcg h\/mL). At trough concentrations of 10 \u03bcg\/mL\u201315\u00a0\u03bcg\/mL, only approximately half of the patients achieved the target AUC\n                      <jats:sub>24<\/jats:sub>\n                      range (400 \u03bcg h\/mL\u2013600\u00a0\u03bcg h\/mL), whereas at troughs of 15 \u03bcg\/mL\u201320\u00a0\u03bcg\/mL, nearly half of the patients exceeded the safe exposure thresholds, underscoring the limitations of trough-based monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      AUC\n                      <jats:sub>24<\/jats:sub>\n                      estimation from peak and trough samples was feasible in routine pediatric workflow, providing more accurate exposure assessment than trough-guided monitoring. Implementation may improve efficacy and minimize nephrotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1790042","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:10:25Z","timestamp":1775513425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of vancomycin AUC24 monitoring using peak and trough concentrations in pediatric patients: a prospective multicenter study"],"prefix":"10.3389","volume":"17","author":[{"given":"Majed H.","family":"Nahari","sequence":"first","affiliation":[{"name":"Pharmaceutical Care Services, King Abdullah bin Abdulaziz University Hospital","place":["Riyadh, Saudi Arabia"]},{"name":"Collage of Pharmacy, Princess Nourah bint Abdulrahman University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Alsultan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renad A.","family":"Alshuraim","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Services, King Saud Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Altuwayjiri","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Services, King Saud Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sultan","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Services, King Salman Specialized Hospital","place":["Taif, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Aljeraisy","sequence":"additional","affiliation":[{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]},{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Science","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s12098-019-03162-5","article-title":"AUC- vs trough-guided monitoring of vancomycin in infants","volume":"87","author":"Alsultan","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/archdischild-2017-314506","article-title":"Pharmacokinetic studies in children: recommendations for practice and research","volume":"103","author":"Barker","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"Impact of AUC-guided dosing on vancomycin-associated nephrotoxicity: a quasi-experiment","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/INF.0000000000001882","article-title":"Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000001159","article-title":"Evaluation of vancomycin dose needed to achieve 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio greater than or equal to 400 using pharmacometric approaches in pediatric intensive care patients","author":"Jung","year":"2024","journal-title":"Crit. Care Explor"},{"key":"B7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jiac.2023.12.021","article-title":"A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients","volume":"30","author":"Kanazawa","year":"2024","journal-title":"J. Infect. Chemother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5863\/1551-6776-22.1.41","article-title":"Vancomycin AUC\/MIC and corresponding troughs in a pediatric population","volume":"22","author":"Kishk","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1093\/jpids\/piu110","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin in children","volume":"4","author":"Le","year":"2015","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004307","article-title":"Optimal vancomycin AUC target in pediatric MRSA bacteremia: a Bayesian-guided approach","author":"Lee","year":"2024","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the IDSA for the treatment of MRSA infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with MRSA bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from trough-guided to AUC-guided vancomycin dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/jac\/dkab242","article-title":"Precision dosing of vancomycin: in defence of AUC-guided therapy in children","volume":"76","author":"Murphy","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B26","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"106109","DOI":"10.1016\/j.ijantimicag.2020.106109","article-title":"Reduced nephrotoxicity with vancomycin TDM guided by AUC vs trough 15\u201320 \u03bcg\/mL","volume":"56","author":"Oda","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv. Drug Delivery Reviews"},{"key":"B16","volume-title":"Vancomycin. In: Statpearls","author":"Patel","year":"2024"},{"key":"B17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.5863\/1551-6776-25.6.476","article-title":"Challenges of vancomycin dosing and therapeutic monitoring in neonates","volume":"25","author":"Pham","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.5863\/1551-6776-24.4.312","article-title":"Vancomycin treatment failure in children with MRSA bacteremia","volume":"24","author":"Regen","year":"2019","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious MRSA infections: revised consensus guideline","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e882","DOI":"10.1093\/infdis\/jiad487","article-title":"Prediction of vancomycin area under the curve with trough concentrations only: performance evaluation of pediatric population pharmacokinetic models","volume":"231","author":"Schouwenburg","year":"2025","journal-title":"J. Infect. Dis."},{"key":"B21","volume-title":"Methicillin-resistant staphylococcus aureus. In: Statpearls","author":"Siddiqui","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12887-023-04317-2","article-title":"Predictive models for sepsis in children with S. aureus bloodstream infections: a retrospective cohort study","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Pediatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40272-018-0282-4","article-title":"The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a systematic review","volume":"20","author":"Tkachuk","year":"2018","journal-title":"Pediatr. Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/bcp.14411","article-title":"Personalized dosing of vancomycin: a prospective and retrospective comparative quasi-experimental study","volume":"87","author":"Vali","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/8755122517747088","article-title":"Incidence and risk factors for vancomycin nephrotoxicity in acutely ill pediatric patients","volume":"34","author":"Woldu","year":"2018","journal-title":"J. Pharm. Technol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1790042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:10:26Z","timestamp":1775513426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1790042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":26,"alternative-id":["10.3389\/fphar.2026.1790042"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1790042","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"1790042"}}